Literature DB >> 24428853

Antibiotic-induced cardiac arrhythmias.

Elsayed Abo-Salem1, John C Fowler, Mehran Attari, Craig D Cox, Alejandro Perez-Verdia, Ragesh Panikkath, Kenneth Nugent.   

Abstract

This review aims to clarify the underlying risk of arrhythmia associated with the use of macrolides and fluoroquinolones antibiotics. Torsades de pointes (TdP) is a rare potential side effect of fluoroquinolones and macrolide antibiotics. However, the widespread use of these antibiotics compounds the problem. These antibiotics prolong the phase 3 of the action potential and cause early after depolarization and dispersion of repolarization that precipitate TdP. The potency of these drugs, as potassium channel blockers, is very low, and differences between them are minimal. Underlying impaired cardiac repolarization is a prerequisite for arrhythmia induction. Impaired cardiac repolarization can be congenital in the young or acquired in adults. The most important risk factors are a prolonged baseline QTc interval or a combination with class III antiarrhythmic drugs. Modifiable risk factors, including hypokalemia, hypomagnesemia, drug interactions, and bradycardia, should be corrected. In the absence of a major risk factor, the incidence of TdP is very low. The use of these drugs in the appropriate settings of infection should not be altered because of the rare risk of TdP, except among cases with high-risk factors.
© 2013 John Wiley & Sons Ltd.

Entities:  

Keywords:  Antibiotics; Fluoroquinolones; Macrolides; QT interval; Torsade de pointes

Mesh:

Substances:

Year:  2014        PMID: 24428853     DOI: 10.1111/1755-5922.12054

Source DB:  PubMed          Journal:  Cardiovasc Ther        ISSN: 1755-5914            Impact factor:   3.023


  19 in total

Review 1.  Targeted Cancer Therapies and QT Interval Prolongation: Unveiling the Mechanisms Underlying Arrhythmic Complications and the Need for Risk Stratification Strategies.

Authors:  Rezarta Cuni; Iris Parrini; Riccardo Asteggiano; Maria Rosa Conte
Journal:  Clin Drug Investig       Date:  2017-02       Impact factor: 2.859

2.  Drug safety of macrolide and quinolone antibiotics in a tertiary care hospital: administration of interacting co-medication and QT prolongation.

Authors:  David Niedrig; Sarah Maechler; Liesa Hoppe; Natascia Corti; Helen Kovari; Stefan Russmann
Journal:  Eur J Clin Pharmacol       Date:  2016-03-29       Impact factor: 2.953

Review 3.  Proarrhythmic and Torsadogenic Effects of Potassium Channel Blockers in Patients.

Authors:  Mark McCauley; Sharath Vallabhajosyula; Dawood Darbar
Journal:  Card Electrophysiol Clin       Date:  2016-03-22

4.  Systematic Review, Meta-analysis, and Network Meta-analysis of the Cardiovascular Safety of Macrolides.

Authors:  Mordechai Muszkat; Ilan Matok; Einat Gorelik; Reem Masarwa; Amichai Perlman; Victoria Rotshild
Journal:  Antimicrob Agents Chemother       Date:  2018-05-25       Impact factor: 5.191

5.  The Value of Macrolide-Based Regimens for Community-Acquired Pneumonia.

Authors:  Alexandra McFarlane; Wendy Sligl
Journal:  Curr Infect Dis Rep       Date:  2015-12       Impact factor: 3.725

6.  Hypokalemia during antibiotic treatment for bone and joint infections.

Authors:  Carmen Falcone; Leonida Compostella; Antonella Camardo; Li Van Stella Truong; Francesco Centofanti
Journal:  Eur J Orthop Surg Traumatol       Date:  2017-10-10

7.  Fluoroquinolones and Cardiovascular Risk: A Systematic Review, Meta-analysis and Network Meta-analysis.

Authors:  Einat Gorelik; Reem Masarwa; Amichai Perlman; Victoria Rotshild; Momen Abbasi; Mordechai Muszkat; Ilan Matok
Journal:  Drug Saf       Date:  2019-04       Impact factor: 5.606

Review 8.  Guidelines for the prevention and treatment of travelers' diarrhea: a graded expert panel report.

Authors:  Mark S Riddle; Bradley A Connor; Nicholas J Beeching; Herbert L DuPont; Davidson H Hamer; Phyllis Kozarsky; Michael Libman; Robert Steffen; David Taylor; David R Tribble; Jordi Vila; Philipp Zanger; Charles D Ericsson
Journal:  J Travel Med       Date:  2017-04-01       Impact factor: 8.490

9.  Erythromycin, QTc interval prolongation, and torsade de pointes: Case reports, major risk factors and illness severity.

Authors:  Jules C Hancox; Mehrul Hasnain; W Victor R Vieweg; Michael Gysel; Michelle Methot; Adrian Baranchuk
Journal:  Ther Adv Infect Dis       Date:  2014-04

Review 10.  Efficacy and safety of azithromycin in Covid-19 patients: A systematic review and meta-analysis of randomized clinical trials.

Authors:  Ahmed M Kamel; Mona S A Monem; Nour A Sharaf; Nada Magdy; Samar F Farid
Journal:  Rev Med Virol       Date:  2021-06-02       Impact factor: 11.043

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.